Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 11, 2012, Pages 1845-1852

  Yildiz, Ramazan ^a   Benekli, Mustafa ^a   Ozkan, Metin ^b   Alkis, Necati ^c   Berk, Veli ^b   Kaplan, Mehmet Ali ^d   Ciltas, Aydin ^a   Karaca, Halit ^b   Durnali, Ayse Gok ^c   Coskun, Ugur ^a   Dikilitas, Mustafa ^b   Sevinc, Alper ^e   Dane, Faysal ^f   Yetisyigit, Tarkan ^c   Dogu, Gamze Gokoz ^b   Buyukberber, Suleyman ^a  

^a GAZI UNIVERSITY   (Turkey)

^b ERCIYES UNIVERSITY   (Turkey)

^c Dr Abdurrahman Yurtaslan Education and Research Hospital   (Turkey)

^d DICLE UNIVERSITY   (Turkey)

^e GAZIANTEP UNIVERSITY   (Turkey)

^f MARMARA UNIVERSITY   (Turkey)

Author keywords

Bevacizumab; FOLFIRI; Metastatic colorectal cancer

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FISTULA; HUMAN; HUMAN TISSUE; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84870405033     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1264-5     Document Type: Article

References (23)

1. Beer PM, Wong SJ, Hammad AM, Falk NS, O'Malley MR, Khan S (2006) Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina 26: 871-876 (Pubitemid 44547438)
2. Bennouna J, Borg C, Delord JP, Husseini F, Trillet-Lenoir V, Faroux R, François E, Ychou M, Goldwasser F, Bouché O, Senellart H, Kraemer S, Douillard JY (2011) Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study. Clin Colorectal Cancer. doi:10.1016/j.clcc.201105.002
3. Bergsland E, Dickler MN (2004) Maximizing the potential of bevacizumab in cancer treatment. Oncologist 9(Suppl 1): 36-42 (Pubitemid 38747846)
4. Borgström P, Gold DP, Hillan KJ, Ferrara N (1999) Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 19: 4203-4214
5. Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, Reimann JD, Vassel A (2003) A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30(Suppl 16): 117-124 (Pubitemid 37433402)
6. Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6 (Pubitemid 20020880)
7. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B, Barrueco J (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25: 4779-4786 (Pubitemid 350086481)
8. Geraci MC (2004) National PBM drug monograph bevacizumab (avastin™). http://www.pbm.va.gov/Clinical%20Guidance/Drug%20Monographs/ Bevacizumab.pdf. Accessed 05 October 2006
9. Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19: 843-850 (Pubitemid 32119100)
10. Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, Kozloff M (2008) Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 26: 5326-5334
11. Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7: 987-989 (Pubitemid 32937367)
12. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21: 60-65
13. Kaplan EL, Meier P (1958) Nonparametric estimation for incomplete observations. J Am Stat Assoc 53: 457-481
14. Kwon HC, Oh SY, Lee S, Kim SH, Kim HJ (2007) Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. World J Gastroenterol 13: 6231-6235
15. Moriwaki T, Bando H, Takashima A, Yamazaki K, Esaki T, Yamashita K, Fukunaga M, Miyake Y, Katsumata K, Kato S, Satoh T, Ozeki M, Baba E, Yoshida S, Boku N, Hyodo I (2011) Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study). Med Oncol. doi:10.1007/s12032-011-0151-2
16. National Cancer Institute Common Toxicity Criteria (NCI-CTC) v3.0. 2006. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3. pdf Accessed 16 November 2007
17. Odabas H, Ozdemir N, Isik M, Abali H, Oksuzoglu B, Kos T, Civelek B, Babacan AN, Dogan U, Zengin N (2011) Safety and efficacy of FOLFIRI-bevacizumab for metastatic colorectal carcinoma as second line treatment. J BUON 16: 460-463
18. Rak JW, St Croix BD, Kerbel RS (1995) Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs 6: 3-18
19. Sher AF, Chu D, Wu S (2009) Risk of bleeding in cancer patients treated with the angiogenesis inhibitor bevacizumab: a meta-analysis. J Clin Oncol 27(Suppl; abstr 9584):15s
20. Sobrero A, Ackland S, Clarke S, Perez-Carrión R, Chiara S, Gapski J, Mainwaring P, Langer B, Young S, AVIRI Trial investigators (2009) Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology 77: 113-119
21. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216 (Pubitemid 30099779)
22. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, Mazier MA, Canon JL, Georgoulias V, Peeters M, Bridgewater J, Cunningham D; First BEAT investigators (2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 20: 1842-1847
23. Yildiz R, Buyukberber S, Uner A, Yamac D, Coskun U, Kaya AO, Ozturk B, Yaman E, Benekli M (2010) Bevacizumab plus irinotecan-based therapy in metastatic colorectal cancer patients previously treated with oxaliplatin-based regimens. Cancer Invest 28: 33-37